Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 9;4(5):e0696.
doi: 10.1097/CCE.0000000000000696. eCollection 2022 May.

Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study

Max Melchers  1 , Arthur R H van Zanten  1   2 , Moniek Heusinkveld  3 , Jan Willem Leeuwis  4 , Roel Schellaars  1 , Hendrick J W Lammers  5 , Freek J Kreemer  6 , Pieter-Jan Haas  7 , Paul E Verweij  8 , Sjoerd H W van Bree  1
Affiliations

Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study

Max Melchers et al. Crit Care Explor. .

Abstract

Despite high mortality rates of COVID-19-associated pulmonary aspergillosis (CAPA) in the ICU, antifungal prophylaxis remains a subject of debate. We initiated nebulized conventional amphotericin B (c-AmB) as antifungal prophylaxis in COVID-19 patients on invasive mechanical ventilation (IMV).

Objectives: To assess the CAPA incidence in COVID-19 patients on IMV treated with and without nebulized c-AmB as antifungal prophylaxis.

Design setting and participants: Retrospective cohort study of consecutive COVID-19 patients admitted to our adult 17-bed ICU in a university-affiliated general hospital in Ede, The Netherlands, between January 25, 2021, and July 9, 2021. Patients not requiring IMV or transferred from or to another ICU were excluded. From April 9, 2021, daily nebulized amphotericin B in all patients on IMV was initiated.

Main outcomes and measures: Bronchoscopy with bronchoalveolar lavage (BAL) was performed in case of positive cultures for Aspergillus from the respiratory tract and/or unexplained respiratory deterioration. Incidence of probable and proven CAPA was compared between patients treated with and without nebulized antifungal prophylaxis using Pearson chi-square test.

Results: A total of 39 intubated COVID-19 patients could be analyzed, of which 16 were treated with antifungal prophylaxis and 23 were not. Twenty-six patients underwent bronchoscopy with BAL. In patients treated with antifungal prophylaxis, the incidence of probable/proven CAPA was significantly lower when compared with no antifungal prophylaxis (27% vs 67%; p = 0.047). Incidence of tracheobronchial lesions and positive Aspergillus cultures and BAL-galactomannan was significantly lower in patients treated with antifungal prophylaxis (9% vs 47%; p = 0.040, 9% vs 53%; p = 0.044, and 20% vs 60%; p = 0.047, respectively). No treatment-related adverse events and no case of proven CAPA were encountered in patients receiving antifungal prophylaxis.

Conclusions and relevance: Nebulization of c-AmB in critically ill COVID-19 patients on IMV is safe and may be considered as antifungal prophylaxis to prevent CAPA. However, a randomized controlled trial to confirm this is warranted.

Keywords: Aspergillus; COVID-19; amphotericin B; antibiotic prophylaxis; intensive care unit; invasive pulmonary aspergillosis.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Flowchart of admitted COVID-19 patients, including main findings regarding COVID-19-associated pulmonary aspergillosis (CAPA) incidence in patients who underwent a bronchoalveolar lavage (BAL) procedure. IMV = invasive mechanical ventilation.
See this image and copyright information in PMC

References

    1. Koehler P, Bassetti M, Chakrabarti A, et al. ; European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada: Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21:e149–e162 - PubMed
    1. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al. : COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med 2020; 202:132–135 - PMC - PubMed
    1. Gangneux JP, Dannaoui E, Fekkar A, et al. : Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study. Lancet Respir Med 2021; 10:180–190 - PMC - PubMed
    1. Xu J, Yang X, Lv Z, et al. : Risk factors for invasive aspergillosis in patients admitted to the intensive care unit with coronavirus disease 2019: A multicenter retrospective study. Front Med (Lausanne) 2021; 8:753659. - PMC - PubMed
    1. Feys S, Almyroudi MP, Braspenning R, et al. : A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA). J Fungi (Basel) 2021; 7:1067. - PMC - PubMed